Meeting Coverage
>
ACG
—
Rifaximin also reduced mortality, but its high cost may be a barrier
by
Tara Haelle, Contributing Writer, MedPage Today
November 1, 2024
Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy compared with lactulose monotherapy, a post-hoc analysis of two randomized trials showed.
Over 6 months, 23.2% of patients receiving rifaximin monotherapy experienced an OHE breakthrough episode compared with 49% of patients receiving lactulose monotherapy (P
Information contained on this page is provided by an independent third-party content provider. This website makes no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact editor @pleasantgrove.business
